From Dr. Steve Kitchen: We have just learned the very sad news that Bob Malia has passed away. I don’t have any more details just now but will come back with addresses, etc. for any messages and details of arrangements when I have these. One of a kind and an inspiration to many of us in the field of Haemostasis and Thrombosis.
Thanks to Dean Willett (Instrumentation Laboratories, Inc) for passing on the sad news.
More on Bob sent by Dr. Kitchen and passed along by Lisa Reid-Fifoot of Precision BioLogic Inc): Bob passed away in his sleep Thursday night without any prior illness. Doreen Malia‘s address is 2 Furnival Close, Todwick, Sheffield, S26 1HE.
I’d like to draw your attention to the numerous and insightful responses to Sylvia Stacy‘s question about applying age-adjusted D-dimer limits to venous thromboembolic disease diagnosis, especially Dr. Giuseppe Lippi’s entry with a link to his brief questionnaire, which he intends to keep open through February, 2015. Let’s give Dr. Lippi as many responses as possible.
I recently received a message from a local colleague who has received complaints from the nursing department when rejecting clotted coagulation specimens. The problem occurs with both citrated blue-closure and EDTA lavender-closure tubes. A few of the nurses are convinced the laboratory is storing the specimens too long before testing them, thus allowing them to become clotted. My colleague has provided in-services explaining the need for gentle specimen mixing immediately after collection, but has been only partially successful in convincing them that they control specimen integrity at the time of collection. I’d like to get responses from participants who face inter-departmental communication issues like this. How do you convince nurses and phlebotomists of the need to prevent hemolysis, short draws, and clotted specimens? Further, do you have any additional advice about managing pediatric specimens?
I received a question recently about Coumadin (warfarin) therapy and coagulation factor half-lives. Coumadin reduces the normal carboxylation of the glutamic acid γ-carbon. There are 12–18 glutamic acid units near the amino terminus of the vitamin K-dependent factors II (prothrombin), VII, IX, and X. When vitamin K-catalyzed γ-carboxylation becomes suppressed, these coagulation factors are unable to bind Ca++ ions and consequently unable to bind platelet phosphatidyl serine, thus becoming ineffective. The same thing happens near the amino termini of control proteins C and S.
Read more »
Hello Mr. Fritsma! My name is Agustin Rodriguez and I am a haematologist from Spain. I have a question for you, if you are so kind to ansxwer it: I have a patient with a lupus anticoagulant. His partial thromboplastin time (PTT, aPTT) is 46 s; normal aPTT is 30 s in my laboratory. The inmediate mixing study 1:1 with normal plasma is 52 s. Can aPTT be more prolonged after mixing with normal plasma than the basal patient aPTT? In most patients with LA, the aPTT fails to correct with normal plasma but there is no prolongation over the initial aPTT. Which is the explanation for this question?
Best regards from Spain, Agustin Rodriguez, MD Haematologist, Toledo Hospital (Virgen de la Salud), Spain.
Read more »
Hi George, I am wondering if anyone is using the age-related D-dimer cutoff for the emergency room based on the ADJUST-PE study? We use Innovance D-dimer reagents from Siemens on the BCS XP analyzer. Our ER physicians are very impatient for us to allow them to use this age-adjusted cut-off, but we have reservations due to CAP and CLIA regulations. Thanks, Sylvia Stacy, Concord Hospital, Concord, NH.
Read more »
According to an October 30 Medscape post, Edoxaban (Savaysa, Daiichi-Sankyo) received a favorable vote, 9–1, in favor of release for once a day treatment at 30 and 60 mg to prevent non-valvular atrial fibrillation ischemic stroke. Edoxaban was found non-inferior to “in control” Coumadin in patients with mild to moderate renal impairment, but its performance in people with creatinine clearances over 80 mL/min was found to be inferior. The advisory committee vote is preliminary to FDA release of edoxaban, the final ruling could be weeks or months away.
From Nancy Fabbrini: We have a patient on an argatroban bridge to warfarin. He is a very difficult draw so the service has been drawing blood from the central access device. They have been withdrawing 20 mL of blood before drawing the tube for coagulation testing. Is that sufficient, i.e. do the same “rules” for a line with heparin apply to argatroban? Thank you.
Read more »